– September 22, 2025

Ouro Medicines has been named one of Fierce Biotech’s “Fierce 15” Biotech Companies of 2025

– August 5, 2025

Ouro Medicines Announces Initiation of OM336 Basket Study in Autoimmune Cytopenias and Granting of U.S. FDA Orphan Drug Designation for OM336 in Autoimmune Hemolytic Anemia (AIHA)

– June 12, 2025

Ouro Medicines Announces a Clinical Trial of OM336 for Autoimmune Cytopenias Following Positive Case Reports in The New England Journal of Medicine

– January 10, 2025

Ouro Medicines Launches to Define the Future of Treatment for People with Immune-Mediated Diseases